Humacyte, Inc. - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
HUMA Nasdaq 3850 www.humacyte.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Humacyte, Inc.

RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates - Nov 5th, 2026 5:00 pm
Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note - Nov 5th, 2026 3:00 pm
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates - Nov 4th, 2026 2:15 pm
Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026 - Nov 3rd, 2026 6:00 am
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights - Oct 30th, 2026 3:00 pm
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues - Oct 28th, 2026 6:00 am
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner - Oct 23rd, 2026 6:00 am
Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today - Oct 21st, 2026 3:00 pm
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note - Oct 19th, 2026 3:15 pm
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals - Oct 15th, 2026 6:00 am
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Oct 13th, 2026 3:15 pm
Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026 - Oct 12th, 2026 6:00 am
Humacyte (HUMA) Stock Fair Value Moves Lower After Analyst Target Cuts - Oct 8th, 2026 11:16 pm
Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls - Oct 7th, 2026 8:00 am
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade - Oct 6th, 2026 3:00 pm
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik - Sep 28th, 2026 6:00 am
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Sep 25th, 2026 3:00 pm
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know - Sep 18th, 2026 4:00 pm
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? - Sep 17th, 2026 7:30 am